pneumococcal disease
Vaccines · 2009–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pneumococcal 21-valent conjugate vaccine Prevention of pneumococcal disease in non-Indigenous adults aged ≥65 years, Aboriginal and Torres Strait Islander adults aged ≥25 years, and adults aged ≥18… | Nov 2025 | Recommended | input received National Aboriginal Community Controlled Health Organisation · Lung Foundation Australia · Immunisation Coalition |
| pneumococcal conjugate vaccine, 15-valent Protection against pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in… | Mar 2023 | Recommended | input received Lung Foundation Australia |
| pneumococcal conjugate vaccine, 20-valent Prevention of pneumococcal disease caused by Streptococcus pneumoniae in paediatric populations including children aged 12 months or younger in specified… | Nov 2023 | Recommended | input received Immunisation Foundation |
| pneumococcal polysaccharide conjugate vaccine, 13-valent Prevention of pneumococcal disease (community-acquired pneumonia and invasive pneumococcal disease) in individuals aged ≥5 to <65 years with at-risk conditions… | Nov 2018 | Not recommended | input received |
| pneumococcal conjugate vaccine, 13-valent Prevention of pneumococcal disease (community-acquired pneumonia and invasive pneumococcal disease) in adults aged 65 years and over (non-Indigenous) and 50… | Jul 2016 | Recommended with restriction | 3 individuals Lung Foundation Australia |
| pneumococcal polysaccharide conjugate vaccine, 13-valent Active immunisation for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (including… | Jul 2010 | Recommended with restriction | unclear |
| pneumococcal polysaccharide conjugate vaccine, 13-valent Active immunisation for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (including… | Jul 2010 | Recommended with restriction | unclear |
| Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed Active immunisation for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in… | Nov 2010 | Recommended with restriction | no section in document |
| pneumococcal polysaccharide conjugate vaccine, 10-valent Immunisation of infants and children from 8 weeks to 2 years of age against disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,… | Jul 2009 | Recommended with restriction | no section in document |
Who spoke
Lung Foundation Australia · Immunisation Foundation · National Aboriginal Community Controlled Health Organisation · Immunisation Coalition
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pneumococcal purified capsular polysaccharidesCAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine 0.5 mL Solution for | 1991 | 6 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.